This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative therapies, particularly in the fields of gastrointestinal and infectious diseases. With a focus on advancing patient care, Optimer is renowned for its flagship product, Dificid (fidaxomicin), which offers a unique treatment option for Clostridium difficile infections. Operating primarily in North America and expanding its reach globally, Optimer Pharmaceuticals has established a strong market position through its commitment to research and development. The company’s dedication to addressing unmet medical needs has garnered recognition within the industry, solidifying its reputation as a leader in specialised pharmaceuticals.
DitchCarbon Score
How does Optimer Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Optimer Pharmaceuticals, Inc.'s score of 69 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Optimer Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is part of a corporate family that includes Merck & Co., Inc., from which it inherits climate-related initiatives and targets. As a merged entity, Optimer Pharmaceuticals aligns its climate commitments with those of Merck & Co., Inc. This includes participation in various sustainability initiatives, although specific reduction targets or achievements for Optimer Pharmaceuticals are not detailed. The emissions data and climate strategies are cascaded from Merck, which is known for its commitment to reducing greenhouse gas emissions across its operations. While no direct emissions data is available for Optimer Pharmaceuticals, the company is expected to adhere to the broader climate strategies set forth by Merck, which may include industry-standard practices and targets aimed at reducing Scope 1, 2, and 3 emissions. The lack of specific data highlights the need for transparency in reporting and commitment to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Optimer Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
